Last reviewed · How we verify
NCT05986422
Methylprednisolone in Patients with Cognitive Deficits in Post-COVID-19 Syndrome (PCS)
Phase 2 trial testing Methylprednisolone in Post-COVID-19 Syndrome in 418 participants. Status unknown.
30 April 2025
Quick facts
| Lead sponsor | Charite University, Berlin, Germany |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 418 |
| Start date | 1 October 2023 |
| Primary completion | 30 April 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- Methylprednisolone (methylprednisolone) — full drug profile →
Conditions studied
- Post-COVID-19 Syndrome — all drugs for Post-COVID-19 Syndrome →
Sponsor
Charite University, Berlin, Germany
Who can join
18 and older, any sex, with Post-COVID-19 Syndrome. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial aims to learn about the therapeutic value of Methylprednisolone, a well-known immunosuppressant, on cognitive deficits in patients with post-COVID-19 syndrome (PCS). The main questions it aims to answer are: 1) Does Methylprednisolone improve memory function in PCS patients compared to placebo? 2) Does Methylprednisolone improve other patient centered outcomes in PCS patients such as fatigue, mood and quality of life compared to placebo? 3)What are the side effects of Methylprednisolone in this patient population, and how common are they? Participants in this study will be patients with PCS and cognitive deficits, who will be asked to participate for 52 weeks. They will be randomly assigned to one of two groups: One group will receive Methylprednisolone once daily for six weeks, with a dosage reduction after week 4. The other group will receive a matching placebo once daily for six weeks, following the same titration regimen to ensure blinding. Participants will attend outpatient follow-up visits in weeks 8 and 20, with a final telephone follow-up after 52 weeks. Clinical examinations and safety monitoring will be conducted during the treatment phase. This study's results may help develop more effective therapies for this condition.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Post-COVID-19 condition: clinical phenotypes, pathophysiological mechanisms, pathology, and management strategies.
Vlaming-van Eijk LE, Tang G, Bourgonje AR, den Dunnen WFA, et al · · 2025 · cited 5× · PMID 40492581 · DOI 10.1002/path.6443
Verify or expand the search:
- PubMed search for NCT05986422
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Methylprednisolone
Trials testing the same drug.
- NCT07072585 — Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leuk · Phase 2, PHASE3 · not yet recruiting
- NCT07455396 — Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Ped · Phase 2 · not yet recruiting
- NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
- NCT07357935 — Early Inflammatory-Immune Stratification and Precision Glucocorticoid Intervention in Acute Respiratory Failure Induced · Phase 1, PHASE2 · not yet recruiting
- NCT07265258 — A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease · Phase 4 · not yet recruiting
Other recruiting trials for Post-COVID-19 Syndrome
Currently open trials in the same condition.
- NCT06156176 — Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial · NA · recruiting
- NCT06231238 — Balance Acceptance and Commitment Therapy for Long COVID · NA · active not recruiting
- NCT06042751 — Psychosomatic, Physical Activity or Both for Post-covid19 Syndrom · NA · active not recruiting
- NCT06073002 — Effects of a Home-Based Exercise Intervention in Subjects with Long COVID · NA · active not recruiting
- NCT05890599 — Yoga Versus Health Education for the Treatment of Persistent Fatigue in Patients With Post COVID-19 Syndrome · NA · recruiting
Other Charite University, Berlin, Germany trials
Trials by the same sponsor.
- NCT07486167 — Influence of Lung Volume Optimization Maneuver on Cardiac Output and Lung Compliance in Ventilated Children With Congeni · Phase 1, PHASE2 · not yet recruiting
- NCT07476729 — International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020) · Phase 3 · not yet recruiting
- NCT07503054 — Ovarian Cancer Screening and AI · NA · not yet recruiting
- NCT07529197 — Observational Study on Immunoadsorption (IA) in Patients With Autoantibody-Positive Post-Infectious ME/CFS · recruiting
- NCT07388693 — Feasibility of Integrating Olfactory Stimuli Into Virtual Reality Cue Exposure for Patients With Alcohol Dependence · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05986422 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Charite University, Berlin, Germany
- Last refreshed: 19 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05986422.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing